News

eTOX

Integrating bioinformatics and chemoinformatics approaches for the development of expert systems allowing the in silico prediction of toxicities

ETOX_Project_logo

The eTOX project was granted as one of the first IMI projects. It has successfully ended its consortium life after 7 years of collaboration between 13 pharma companies, 11 academia institutions and 6 SMEs.

The eTOX project as IMI consortium has been completed with the accomplishment of an effective synergic sharing of historical toxicological data within the pharmaceutical industry. It created a series of models to support toxicity prediction. Both data and models are integrated in the platform developed in the project, the eTOXsys™, which is a powerful system to access the eTOX data and the predictive models.

 

eTOX FACTS and FIGURES

  • 15 Consortium meetings, 1 Mid-term Review, 7 eTOXsys user meetings, 1 modelling workshop and 2 Hackathons were celebrated.
  • 15 releases of the Vitic Nexus eTOX database were delivered. The final version contains 1,947 substances (483 labelled as confidential) and 8,047 study design records from 6,971 legacy reports; and 265,502 substances and 1,088,007 records from public sources like ChEMBL, DrugMatrix and Open TG-GATES.
  • Technical synchronization between OntoBrowser, Vitic Nexus eTOX database and eTOXsys regarding the Terminology (SEND codelists and INHAND controlled vocabularies) harmonization allowed the mapping of around 20 millions of verbatim terms to 7,262 preferred terms, which highly improves the quality of read across analysis and data stratification for modelling challenges.
  • Several tools were developed and are freely accessible for the scientific community benefit.
  • 5 releases of the eTOXsys were launched. The final version includes the 2016.3 Vitic release, a bunch of 200 predictive models, and the Human Outcomes Module integrated, which was designed to support and open a door for translational research from preclinical to clinical research.

 

eTOX video

 

eTOX launches a video presenting the 2nd hackathon event held at the PRBB, which also gives an insight into the project.

 

 

 

eTOX Final Consortium Meeting – Pierre Meulien Keynote

 

eTOX Final Consortium Meeting was held in Basel (Switzerland) on the 29th of November 2016. Pierre Meulien, IMI Executive Director, gave a Keynote with the title: Current strategies and implementation of the IMI-2 programme.

 

 

 

Funding

 

eTOX, under Grant Agreement nº115002, is funded by the Innovative Medicines Initiative Joint Undertaking (IMI-JU), a unique partnership between the European Community and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

EU-logo-00efpia-logo-00IMI-logo-00